Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. JCAP
JCAP logo

JCAP Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
21.360
Open
20.500
VWAP
20.89
Vol
411.04K
Mkt Cap
1.30B
Low
20.210
Amount
8.59M
EV/EBITDA(TTM)
7.45
Total Shares
61.63M
EV
2.37B
EV/OCF(TTM)
8.75
P/S(TTM)
3.18
Jefferson Capital, Inc. is an analytically driven purchaser and manager of charged-off and insolvency consumer accounts with operations primarily in the United States, Canada, the United Kingdom and Latin America. The accounts it purchases are primarily the unpaid obligations of individuals owed to credit grantors, which include banks, non-bank consumer lenders, auto finance companies, utilities and telecom companies. The Company purchases nonperforming consumer loans and receivables at a discount to their face value across a broad range of financial assets, including where the account holder has initiated a bankruptcy proceeding, or an equivalent proceeding in Canada or the United Kingdom. It enables its clients to focus their operations on the origination of new loans to new customers and to better serve their active customers, while also enabling consumers to resolve their existing obligations based on their current financial circumstances.
Show More

Events Timeline

(ET)
2026-01-08
06:20:00
Jefferies and Keefe Bruyette Jointly Manage Offering
select
2026-01-05 (ET)
2026-01-05
19:00:00
Aeva Stock Rises 26.8% After Announcing 4D LiDAR Integration with NvidiaDrive Hyperion
select
2026-01-05
16:30:00
Jefferson Capital Plans to Offer 10M Shares in Secondary Offering
select
2026-01-05
16:20:00
Jefferson Capital files to sell 10M shares of common stock for holders
select
2025-11-13 (ET)
2025-11-13
16:37:39
Jefferson Capital announces Q3 adjusted EPS of 74 cents, surpassing consensus estimate of 62 cents.
select

News

Globenewswire
8.5
01-08Globenewswire
Jefferson Capital Prices 10M Share Offering at $20.50 Each
  • Offering Size: Jefferson Capital announced a public offering of 10 million shares at $20.50 each, potentially raising $205 million to strengthen its capital structure for future acquisitions and investments.
  • Additional Purchase Option: Underwriters have a 30-day option to purchase an additional 1.5 million shares, which, if exercised, would further increase total capital and enhance market demand and liquidity for the stock.
  • Share Repurchase Plan: Concurrently, Jefferson Capital will repurchase 3 million shares at the same price from underwriters, indicating confidence in its stock and potentially boosting earnings per share.
  • Underwriter Lineup: The offering is managed by notable financial institutions including Jefferies and Keefe, Bruyette & Woods, reflecting strong market interest and trust in the transaction.
Globenewswire
8.5
01-05Globenewswire
Jefferson Capital Plans to Offer 10 Million Shares in Secondary Offering
  • Stock Offering Plan: Jefferson Capital intends to sell 10 million shares of common stock in an underwritten secondary offering, which is expected to provide liquidity to existing shareholders and enhance market confidence.
  • Additional Purchase Option: Underwriters will have a 30-day option to purchase an additional 1.5 million shares, further increasing market participation and potentially enhancing stock liquidity.
  • Share Repurchase Plan: Jefferson Capital plans to concurrently repurchase 3 million shares of common stock at the price paid by underwriters to selling shareholders, which will reduce the number of shares outstanding and may enhance earnings per share.
  • Underwriter Lineup: The secondary offering is being managed by Jefferies and Keefe, Bruyette & Woods as joint-lead book-running managers, reflecting strong market confidence and support for the company.
Benzinga
8.5
2025-12-31Benzinga
Cybin Inc Launches $100 Million Equity Program, Shares Drop 6.6%
  • Stock Decline: Cybin Inc's shares fell 6.6% to $8.00 in pre-market trading following the announcement of a $100 million at-the-market equity program with Cantor Fitzgerald, which may undermine investor confidence and complicate future fundraising efforts.
  • Market Reaction: The drop in Cybin's stock price reflects investor concerns regarding the new financing plan, potentially impacting the company's capital operations and shareholder value moving forward.
  • Industry Impact: Concurrently, other biotech firms like Corcept Therapeutics and NovaBay Pharmaceuticals also experienced stock declines, indicating a cautious sentiment across the biotech sector that could affect the overall fundraising environment.
  • Investor Focus: The lukewarm market response to Cybin's financing initiative may prompt the company to reassess its capital structure and financing strategies to navigate current market challenges.
Benzinga
5.0
2025-12-31Benzinga
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
  • FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
  • Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
  • Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
  • Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
NASDAQ.COM
6.0
2025-12-25NASDAQ.COM
Jefferson Capital's Price Target Raised by 19.37%
  • Analyst Rating Reaffirmed: On December 24, 2025, Keefe, Bruyette & Woods reiterated their 'Outperform' rating on Jefferson Capital (NasdaqGS:JCAP), indicating strong confidence in its future performance.
  • Price Target Forecast: As of December 22, 2025, the average one-year price target for Jefferson Capital is $27.34/share, representing a 19.37% upside from its latest closing price of $22.90/share, reflecting optimistic market expectations for its growth potential.
  • Increase in Institutional Holdings: The number of funds or institutions reporting positions in Jefferson Capital increased by 20, or 29.85%, in the last quarter, indicating a growing interest among investors in the company.
  • Shareholding Changes: William Blair Investment Management increased its holdings by 35.09% to 1,394K shares, while Adage Capital Partners raised theirs by 32.08% to 1,219K shares, demonstrating enhanced confidence among institutional investors in Jefferson Capital.
Yahoo Finance
3.0
2025-12-09Yahoo Finance
Is Jefferson Capital Still a Good Buy Following Its Recent Share Price Increase?
  • Stock Performance: Jefferson Capital's stock has shown a gradual increase, with a 0.3% rise over the past week, 7.0% over the month, and 12.3% year-to-date, indicating a positive reassessment by the market.

  • Valuation Insights: The company is currently rated with a 5/6 valuation score, suggesting it is undervalued, with an intrinsic value estimated to be 61.9% above its current share price based on the Excess Returns model.

  • PE Ratio Comparison: Jefferson Capital's price-to-earnings (PE) ratio of 7.48x is below industry averages, indicating it is inexpensive relative to peers, and its current multiple is significantly lower than its Fair Ratio, suggesting the market is not fully recognizing its growth potential.

  • Narrative Framework: Investors can utilize a Narrative framework to connect their beliefs about Jefferson Capital's future performance with financial forecasts, allowing for a more personalized assessment of the stock's fair value compared to its current price.

Wall Street analysts forecast JCAP stock price to rise
4 Analyst Rating
Wall Street analysts forecast JCAP stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
26.00
Averages
27.25
High
29.00
Current: 0.000
sliders
Low
26.00
Averages
27.25
High
29.00
Texas Capital
NULL
to
Buy
initiated
$28
AI Analysis
2026-02-10
Reason
Texas Capital
Price Target
$28
AI Analysis
2026-02-10
initiated
NULL
to
Buy
Reason
Texas Capital initiated coverage of Jefferson Capital with a Buy rating and $28 price target, which implies 29% total return when including the dividend. Jefferson is a technology enabled buyer and processor of charged-off, insolvency, and active consumer receivables, the analyst tells investors in a research note. The firm says the company has reported more consistent operating results relative to peers. It sees an attractive valuation given Jefferson's "high margin franchise."
Keefe Bruyette
Outperform
maintain
$28
2025-12-23
Reason
Keefe Bruyette
Price Target
$28
2025-12-23
maintain
Outperform
Reason
Keefe Bruyette is positive on shares of Jefferson Capital heading into 2026. The firm reiterates an Outperform rating on the name with a $28 price target. Jefferson is well positioned to benefit from a continued normalization in the U.S. and international credit cycle, the analyst tells investors in a research note. Keefe is "constructive" on industry fundamentals as supply increases and believes the company is "industry-leading cash efficiency ratio should continue to drive strong returns."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for JCAP
Unlock Now

Valuation Metrics

The current forward P/E ratio for Jefferson Capital Inc (JCAP.O) is 7.99, compared to its 5-year average forward P/E of 6.70. For a more detailed relative valuation and DCF analysis to assess Jefferson Capital Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
6.70
Current PE
7.99
Overvalued PE
8.59
Undervalued PE
4.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
6.28
Current EV/EBITDA
6.89
Overvalued EV/EBITDA
8.00
Undervalued EV/EBITDA
4.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.67
Current PS
1.95
Overvalued PS
2.14
Undervalued PS
1.21

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks with strong buy
Intellectia · 9 candidates
Market Cap: >= 1000.00MDividend Yield Ttm: >= 1Analyst Consensus: Strong BuyWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20Annual Eps Yoy Growth: >= 15.0%Annual Revenue Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
RY logo
RY
Royal Bank of Canada
235.24B
NEM logo
NEM
Newmont Corporation
129.76B
AU logo
AU
Anglogold Ashanti PLC
51.18B
NLY logo
NLY
Annaly Capital Management Inc
16.28B
PR logo
PR
Permian Resources Corp
12.13B
BANC logo
BANC
Banc of California Inc
3.28B

Whales Holding JCAP

N
North Reef Capital Management LP
Holding
JCAP
+3.85%
3M Return
N
Nantahala Capital Management, LLC
Holding
JCAP
-2.95%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Jefferson Capital Inc (JCAP) stock price today?

The current price of JCAP is 21.1 USD — it has increased 3.74

What is Jefferson Capital Inc (JCAP)'s business?

Jefferson Capital, Inc. is an analytically driven purchaser and manager of charged-off and insolvency consumer accounts with operations primarily in the United States, Canada, the United Kingdom and Latin America. The accounts it purchases are primarily the unpaid obligations of individuals owed to credit grantors, which include banks, non-bank consumer lenders, auto finance companies, utilities and telecom companies. The Company purchases nonperforming consumer loans and receivables at a discount to their face value across a broad range of financial assets, including where the account holder has initiated a bankruptcy proceeding, or an equivalent proceeding in Canada or the United Kingdom. It enables its clients to focus their operations on the origination of new loans to new customers and to better serve their active customers, while also enabling consumers to resolve their existing obligations based on their current financial circumstances.

What is the price predicton of JCAP Stock?

Wall Street analysts forecast JCAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JCAP is27.25 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Jefferson Capital Inc (JCAP)'s revenue for the last quarter?

Jefferson Capital Inc revenue for the last quarter amounts to 103.23M USD, increased 33.45

What is Jefferson Capital Inc (JCAP)'s earnings per share (EPS) for the last quarter?

Jefferson Capital Inc. EPS for the last quarter amounts to 0.66 USD, increased 15.79

How many employees does Jefferson Capital Inc (JCAP). have?

Jefferson Capital Inc (JCAP) has 0 emplpoyees as of March 05 2026.

What is Jefferson Capital Inc (JCAP) market cap?

Today JCAP has the market capitalization of 1.30B USD.